Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-9ie6raooKQQtpoVtcv_jt2kZy239Id5fMEgRCGvOR-zGFVUwknRtwBcPy-Pk2lO-ydCT1VgfcW89TT4MDU_jORuZ_9aQ&_hsmi=342251140&utm_content=342244831&utm_source=hs_email